These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22363887)

  • 21. Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease.
    Drent ML; Jakobsdottir S; van Wijk JAE; Oostdijk W; Wit JM
    Clin Drug Investig; 2002 Sep; 22(9):633-638. PubMed ID: 29492857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. User trial of Easypod, an electronic autoinjector for growth hormone.
    Tauber M; Payen C; Cartault A; Jouret B; Edouard T; Roger D
    Ann Endocrinol (Paris); 2008 Dec; 69(6):511-6. PubMed ID: 18589398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
    Pawlikowska-Haddal A
    Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developments in administration of growth hormone treatment: focus on Norditropin® Flexpro®.
    Yuen KC; Amin R
    Patient Prefer Adherence; 2011 Mar; 5():117-24. PubMed ID: 21448295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient acceptability of a new 3.0 ml pre-filled insulin pen.
    D'Eliseo P; Blaauw J; Milicević Z; Wyatt J; Ignaut DA; Malone JK
    Curr Med Res Opin; 2000; 16(2):125-33. PubMed ID: 10893656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.
    Bozzola M; Colle M; Halldin-Stenlid M; Larroque S; Zignani M;
    BMC Endocr Disord; 2011 Feb; 11():4. PubMed ID: 21294891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding and meeting the needs of those using growth hormone injection devices.
    Dumas H; Panayiotopoulos P; Parker D; Pongpairochana V
    BMC Endocr Disord; 2006 Oct; 6():5. PubMed ID: 17034628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erratum: User assessment of Norditropin NordiFlex®, a new prefilled growth hormone pen: a Phase IV multicenter prospective study [Corrigendum].
    Patient Prefer Adherence; 2013; 7():803. PubMed ID: 23983458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes.
    McKay M; Compion G; Lytzen L
    Diabetes Technol Ther; 2009 Mar; 11(3):195-201. PubMed ID: 19267582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings.
    Aronson R; Gibney MA; Oza K; Bérubé J; Kassler-Taub K; Hirsch L
    Clin Ther; 2013 Jul; 35(7):923-933.e4. PubMed ID: 23790553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Use of PenNeedle(®) 32G Taper in Children being Treated with Growth Hormone.
    Ida S; Yoshimura N; Nakacho M; Ota M; Mine H; Moriyama H; Terao N; Ueda C; Ohno M
    Clin Pediatr Endocrinol; 2008; 17(1):1-7. PubMed ID: 24790355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
    J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient acceptance and issues of education of two durable insulin pen devices.
    Asakura T; Seino H; Jensen KH
    Diabetes Technol Ther; 2008 Aug; 10(4):299-304. PubMed ID: 18715204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients.
    Schnabel D; Partsch CJ; Houang M; Ehtisham S; Johnstone H; Zabransky M; Kiess W
    Med Devices (Auckl); 2016; 9():317-24. PubMed ID: 27660496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety Evaluation of Human Growth Hormone Therapy in Patients with Idiopathic Short Stature in Korea - A Randomised Controlled Trial.
    Jung MH; Suh BK; Ko CW; Lee KH; Jin DK; Yoo HW; Hwang JS; Chung WY; Han HS; Prusty V; Kim HS
    Eur Endocrinol; 2020 Apr; 16(1):54-59. PubMed ID: 32595770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical response and patient acceptance of a prefilled, disposable insulin pen injector for insulin-treated diabetes.
    Chen HS; Hwu CM; Kwok CF; Yang HJ; Shih KC; Lin BJ; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):455-60. PubMed ID: 10418181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients' perceptions on the usability of the SurePal™ self-injection device for Omnitrope
    Coutant R; Dupuis C; Pigeon P; Rebaud P
    Ther Adv Endocrinol Metab; 2017 Sep; 8(9):129-137. PubMed ID: 29051812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study.
    Partsch CJ; Schnabel D; Ehtisham S; Johnstone HC; Zabransky M; Kiess W
    Med Devices (Auckl); 2015; 8():389-93. PubMed ID: 26405430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Patient Experiences with Respimat
    Taube C; Bayer V; Zehendner CM; Valipour A
    Pulm Ther; 2020 Dec; 6(2):371-380. PubMed ID: 32857327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.